New, tolerable γ-secretase inhibitor takes desmoid down a notch

Clinical Cancer Research

Volumn 21, Issue 1, 2015, Pages 7-9

  Hughes, Dennis P M ^a   Kummar, Shivaani ^b   Lazar, Alexander J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; MK 0752; N (6,7 DIHYDRO 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL) 2,2 DIMETHYL N' (2,2,3,3,3 PENTAFLUOROPROPYL)PROPANEDIAMIDE; NOTCH RECEPTOR; PF 3084014; WNT PROTEIN; ENZYME INHIBITOR; SECRETASE; TETRALIN DERIVATIVE; VALINE;

ARTICLE; BETA CATENIN GENE; CTNNB1 GENE; DESMOID TUMOR; DRUG SAFETY; DRUG TOLERABILITY; EXOME; EXON; FATIGUE; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; GENE SEQUENCE; HUMAN; MONOTHERAPY; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; SARCOMA; SIGNAL TRANSDUCTION; SOLID TUMOR; TREATMENT RESPONSE; UTERUS SARCOMA; WNT GENE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; FEMALE; MALE; NEOPLASMS;

AMYLOID PRECURSOR PROTEIN SECRETASES; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; NEOPLASMS; TETRAHYDRONAPHTHALENES; VALINE;

EID: 84920540454     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1660     Document Type: Article

References (11)

1. Messersmith WA, Shapiro GI, Cleary JM, Jimeno A, Dasari A, Huang B, et al. A phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014. Clin Cancer Res 2015;21:60-70.
2. Benedito R, Hellström M. Notch as a hub for signaling in angiogenesis. Exp Cell Res 2013;319:1281-8.
3. Capaccione KM, Pine SR. The Notch signaling pathway as a mediator of tumor survival. Carcinogenesis 2013;34:1420-30.
4. Zhang P, Yang Y, Nolo R, Zweidler-McKay PA, Hughes DP. Regulation of NOTCH signaling by reciprocal inhibition of HES1 and Deltex 1 and its role in osteosarcoma invasiveness. Oncogene 2010;29:2916-26.
5. South AP, Cho RJ, Aster JC. The double-edged sword of Notch signaling in cancer. Semin Cell Dev Biol 2012;23:458-64.
6. De Strooper B, Iwatsubo T, Wolfe MS. Presenilins and γ-secretase: structure, function, and role in Alzheimer disease. Cold Spring Harb Perspect Med 2012;2:a006304.
7. Takebe N, Nguyen D, Yang SX. Targeting Notch signaling pathway in cancer: clinicaldevelopment advances and challenges. Pharmacol Ther 2014;141:140-9.
8. Krop I, Demuth T, Guthrie T, Wen PY, Mason WP, Chinnaiyan P, et al. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol 2012;30: 2307-13.
9. Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG, et al. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol 2012;30: 2348-53.
10. Lazar AJ, Tuvin D, Hajibashi S, Habeeb S, Bolshakov S, Mayordomo- Aranda E, et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol 2008;173:1518-27.
11. Kluk MJ, Ashworth T, Wang H, Knoechel B, Mason EF, Morgan EA, et al. Gauging NOTCH1 activation in cancer using immunohistochemistry. PLoS One 2013;8:e67306.